Entera Bio Ltd. (ENTX): R&D Expense
$6.00M
Year ended 2025-12-31
$8.81M
Trailing 12 months to 2026-06-30
+0.9%
3-year compound annual growth
-1.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.00M | +33.5% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $4.50M | -0.2% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $4.51M | -22.9% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $5.85M | -13.6% | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | $6.77M | +6.1% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $6.38M | n/a | 2022-03-08, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $6.00M | +33.5% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $20.66M | -37.7% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $37.59M | +9.4% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $3.92M | -36.7% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $4.19M | -16.6% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $3.13M | +127.7% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $60.22M | +10.8% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $2.26M | -5.9% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $35.33M | -4.1% |
Compare ENTX, INMB, SNTI, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗